Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial-Reference-Cited by-同舟云学术

Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial

Published:2023-09-22 Issue:2 Volume:22 Page:1723-1730
ISSN:2251-6581
Container-title:Journal of Diabetes & Metabolic Disorders
language:en
Short-container-title:J Diabetes Metab Disord

Author:

Taheri Homa,Chiti Hossein,Reshadmanesh Tara,Gohari Sepehr,Jalilvand Ahmad,Arsang-Jang Shahram,Ismail-Beigi Faramarz,Ghanbari Samin,Dadashi Mohsen,Asgari Atieh,Mahjani Mahsa,Karbalaee‑Hasani Amir,Ahangar Hassan

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40200-023-01305-2.pdf

Reference37 articles.

1. Lazar DR, Lazar F-L, Homorodean C, Cainap C, Focsan M, Cainap S, et al. High-sensitivity troponin: a review on characteristics, assessment, and clinical implications. Dis Markers. 2022;2022.

2. Hillis GS, Welsh P, Chalmers J, Perkovic V, Chow CK, Li Q, et al. The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care. 2014;37(1):295–303.

3. Chilton R, Tikkanen I, Cannon C, Crowe S, Woerle H, Broedl U, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17(12):1180–93.

4. Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract. 2019;150:8–16.

5. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empagliflozin Effects in Patients with ST-Elevation Myocardial Infarction Undergoing Primary PCI: The EMI-STEMI Randomized Clinical Trial;American Journal of Cardiovascular Drugs;2024-07-05

2. Revealing the hidden threat behind detectable cardiac troponin levels in the emergency department;Heart;2024-07-01

3. Novel Therapeutics for Type 2 Diabetes Mellitus—A Look at the Past Decade and a Glimpse into the Future;Biomedicines;2024-06-21

4. Troponin in Heart Failure: Innocent Bystander or Harbinger of Risk?;Journal of Cardiac Failure;2024-06

5. Evaluation of the prevalence of cardiometabolic disorders (diabetes, hypertension, and hyperlipidemia) diagnosed, undiagnosed, treated, and treatment goal in the elderly: Bushehr Elderly Health Program (BEH);BMC Endocrine Disorders;2024-03-05